Australia's most trusted
source of pharma news
Sunday, 19 April 2026
Posted 3 September 2025 AM
A new Novo Nordisk study has crowned inflammation as a stronger predictor of mortality than cholesterol in people with atherosclerotic cardiovascular disease (ASCVD), further challenging the traditional focus on cholesterol alone.
Results of the Swedish observational study were presented by Karolinska Institute in collaboration with the Danish GLP-1 drugmaker at the European Society of Cardiology (ESC) Congress 2025 held over the weekend in Madrid, Spain.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.